Jason J Luke

Jason J Luke

UNVERIFIED PROFILE

Are you Jason J Luke?   Register this Author

Register author
Jason J Luke

Jason J Luke

Publications by authors named "Jason J Luke"

Are you Jason J Luke?   Register this Author

71Publications

2191Reads

38Profile Views

Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.

Authors:
Jason J Luke

Oncologist 2019 Nov 7;24(11):e1197-e1211. Epub 2019 May 7.

Department of Medicine, Division of Hematology/Oncology, University of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0876DOI Listing
November 2019

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.

J Immunother Cancer 2019 Nov 8;7(1):295. Epub 2019 Nov 8.

Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0780-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839232PMC
November 2019

Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.

Future Oncol 2019 Sep 25;15(25):2933-2942. Epub 2019 Feb 25.

Cardinal Health Specialty Solutions, Dublin, OH 43017, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0964DOI Listing
September 2019

Tumor-reprogrammed resident T cells resist radiation to control tumors.

Nat Commun 2019 Sep 2;10(1):3959. Epub 2019 Sep 2.

Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-11906-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718618PMC
September 2019

The newest treatments for uveal melanoma.

Authors:
Jason J Luke

Clin Adv Hematol Oncol 2019 Sep;17(9):490-493

UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

Source
September 2019

STING pathway agonism as a cancer therapeutic.

Immunol Rev 2019 07;290(1):24-38

Department of Pathology, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814203PMC
July 2019

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.

Clin Cancer Res 2019 May 11;25(10):3074-3083. Epub 2019 Jan 11.

Department of Medicine, The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522301PMC
May 2019

The Impact of the Fecal Microbiome on Cancer Immunotherapy.

BioDrugs 2019 Feb;33(1):1-7

Department of Medicine, University of Chicago, 5841 S. Maryland Ave. MC2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40259-018-0328-8DOI Listing
February 2019

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.

Immunotherapy 2019 02;11(3):155-159

Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0171DOI Listing
February 2019

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.

J Natl Compr Canc Netw 2019 Feb;17(2):114-117

bDepartment of Medicine, University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7070DOI Listing
February 2019

Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies.

J Immunother Cancer 2019 01 6;7(1). Epub 2019 Jan 6.

Department of Medicine, University of Chicago, 5841 S. Maryland Ave. MC2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0484-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322234PMC
January 2019

Reply to S.C. Formenti et al.

J Clin Oncol 2018 09 5;36(25):2662-2663. Epub 2018 Jun 5.

Jason J. Luke and Steven J. Chmura, University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.0980DOI Listing
September 2018

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

J Clin Oncol 2018 Sep 28:JCO2018789602. Epub 2018 Sep 28.

Tara C. Mitchell, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Omid Hamid and Ani S. Balmanoukian, The Angeles Clinic and Research Institute, Los Angeles, CA; David C. Smith, University of Michigan, Ann Arbor, MI; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Jeffrey S. Wasser, University of Connecticut School of Medicine, Farmington, CT; Jason J. Luke and Thomas F. Gajewski, University of Chicago Medicine, Chicago, IL; Emmett V. Schmidt, Merck & Co, Kenilworth, NJ; and Yufan Zhao, Xiaohua Gong, Janet Maleski, and Lance Leopold, Incyte Corporation, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225502PMC
September 2018

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

J Clin Oncol 2018 06 13;36(16):1611-1618. Epub 2018 Feb 13.

Jason J. Luke, Jeffrey M. Lemons, Theodore G. Karrison, Sean P. Pitroda, James M. Melotek, Yuanyuan Zha, Hania A. Al-Hallaq, Ainhoa Arina, Nikolai N. Khodarev, Linda Janisch, Paul Chang, Jyoti D. Patel, Gini F. Fleming, John Moroney, Manish R. Sharma, Mark J. Ratain, Thomas F. Gajewski, Ralph R. Weichselbaum, and Steven J. Chmura, The University of Chicago, Chicago, IL; Julia R. White, The Ohio State University, Columbus, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978468PMC
June 2018

The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent.

Int J Breast Cancer 2018 16;2018:4786819. Epub 2018 May 16.

Department of Radiation Oncology, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4786819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976948PMC
May 2018

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.

J Immunother Cancer 2018 04 4;6(1):24. Epub 2018 Apr 4.

Department of Medicine, Section of Hematology/Oncology, Comprehensive Cancer Center, University of Chicago Medicine, 5841 S. South Maryland Avenue, MC 2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0
Publisher Site
http://dx.doi.org/10.1186/s40425-018-0334-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883337PMC
April 2018

Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Nat Rev Clin Oncol 2017 Aug 4;14(8):463-482. Epub 2017 Apr 4.

Melanoma Institute Australia, The University of Sydney, and The Mater Hospital, Rocklands Road, North Sydney, New South Wales 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.43DOI Listing
August 2017

Recent insights into the use of combination immunotherapy in solid tumors.

Authors:
Jason J Luke

Clin Adv Hematol Oncol 2017 Aug;15(8):588-591

The University of Chicago, Chicago, Illinois.

View Article

Download full-text PDF

Source
August 2017

The Phoenix Rises: The Rebirth of Cancer Immunotherapy.

Clin Chem 2017 07 17;63(7):1190-1195. Epub 2017 May 17.

Professor, Internal Medicine, Leader, Melanoma/Renal Cell Disease Research Team, Associate Chief, Section of Medical Oncology, Yale University, New Haven, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2016.267849DOI Listing
July 2017

Mechanistic and pharmacologic insights on immune checkpoint inhibitors.

Pharmacol Res 2017 Jun 18;120:1-9. Epub 2017 Mar 18.

Department of Medicine, Section of Hematology/Oncology, Comprehensive Cancer Center, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2017.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419683PMC
June 2017

Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.

Curr Oncol Rep 2016 11;18(11):67

University of Chicago Comprehensive Cancer Center, 5841 S. Maryland Ave. MC2115, Chicago, IL, 60637, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-016-0554-5
Publisher Site
http://dx.doi.org/10.1007/s11912-016-0554-5DOI Listing
November 2016

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.

J Immunother Cancer 2016 21;4:35. Epub 2016 Jun 21.

Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL 60637 USA ; Department of Pathology, University of Chicago, 5841 S. Maryland Ave, MC2115, Chicago, IL 60637 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0140-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915048PMC
June 2016

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.

Cancer Immunol Res 2015 Sep 5;3(9):986-91. Epub 2015 May 5.

Melanoma Disease Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561189PMC
September 2015

PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.

Oncotarget 2015 Feb;6(6):3479-92

Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414130PMC
http://dx.doi.org/10.18632/oncotarget.2980DOI Listing
February 2015

Have we won the race in the treatment of advanced melanoma-or are we just learning to walk?

Authors:
Jason J Luke

Oncology (Williston Park) 2015 Feb;29(2):136, 138-9

View Article

Download full-text PDF

Source
February 2015

The biology and clinical development of MEK inhibitors for cancer.

Drugs 2014 Dec;74(18):2111-28

Melanoma and Developmental Therapeutics Clinics, University of Chicago Cancer Center, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL, 60637, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-014-0315-4DOI Listing
December 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

J Natl Cancer Inst 2014 Aug 8;106(8). Epub 2014 Aug 8.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JJL, GRO, CPP, BEJ), Memorial Sloan-Kettering Cancer Center, New York, NY (DBS), University of Colorado Cancer Center, Denver, CO (DRC); The University of Texas MD Anderson Cancer Center, Houston, TX (JVH).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281080PMC
August 2014

New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.

Drug Healthc Patient Saf 2014 24;6:77-88. Epub 2014 Jun 24.

Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DHPS.S39568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075957PMC
July 2014

Chemotherapy in the management of advanced cutaneous malignant melanoma.

Clin Dermatol 2013 May-Jun;31(3):290-7

Department of Medicine, Melanoma and Sarcoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2012.08.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709980PMC
November 2013

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

J Clin Oncol 2013 Sep 17;31(26):3182-90. Epub 2013 Jun 17.

F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.7836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878082PMC
September 2013

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Oncologist 2013 Jun 24;18(6):717-25. Epub 2013 May 24.

Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063399PMC
June 2013

Advances in the systemic treatment of cutaneous sarcomas.

Semin Oncol 2012 Apr;39(2):173-83

Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2012.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882013PMC
April 2012

Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.

Clin Cancer Res 2012 Jan 14;18(1):9-14. Epub 2011 Nov 14.

Melanoma and Sarcoma Service, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2197DOI Listing
January 2012

Episode-based payment for cancer care: a proposed pilot for Medicare.

Health Aff (Millwood) 2011 Mar;30(3):500-9

Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1377/hlthaff.2010.0752DOI Listing
March 2011